Project Grant P01CA298971
Award Date 3/5/26
Completion Date 2/28/31
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to develop functional signatures of post-infusion Chimeric Antigen Receptor (CAR) T cells for early indication of patient response. The project, which commenced September 1, 2025 and concludes August 31, 2026, leverages Cellchorus' proprietary Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) platform—an artificial...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $1.85 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 19, 2025, through August 31, 2029. This award supports the development and clinical advancement of chimeric antigen receptor natural killer (CAR-NK) cell therapies targeting CD5-positive T-cell malignancies. The project delivers a novel engineered CAR-NK cell product...
- Federal Grant Award Summary Mucommune LLC received a $2.29 million Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 16, 2025, with a completion date of August 31, 2027. The award supports development of in vivo-engineered B7-H3 chimeric antigen receptor T-cell (CAR-T) therapies for pancreatic ductal adenocarcinoma (PDAC) treatment. Rather than the conventional ex vivo approach requiring harvesting, activation, and...
- Federal Project Grant Award Summary The National Cancer Institute awarded $627,676 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) to develop and validate genetically-encoded biosensors for measuring intercellular heterogeneity in cancer cell cycle quiescence. The three-year project (September 1, 2025 – August 31, 2028) will produce quiescence depth biosensors capable of distinguishing between shallow and deep quiescent states in...
- Federal Project Grant Award Summary Mucommune LLC received a $1,031,566 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 11, 2025, with a completion date of August 31, 2027. The grant supports development of in vivo-engineered B7-H3 chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer treatment. Rather than using conventional ex vivo manufacturing approaches, Mucommune's Nipah lentiviral vector platform...
- Federal Grant Award Summary The National Cancer Institute awarded University of Maryland, Baltimore a $422,799 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 5, 2025, through August 31, 2027. The award supports research on therapeutic targeting and biophysical characterization of Chimeric Antigen Receptor (CAR)-mediated trogocytosis, a resistance mechanism that undermines the efficacy of CAR T cell therapy for blood cancers. The research will...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88M Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on September 23, 2025, with completion targeted for August 31, 2029. The grant funds fundamental research investigating glioblastoma (GBM) predisposition by integrating genome-wide association study (GWAS) data with single-cell omics analyses to identify cellular effectors...
- Federal Grant Award Summary The National Cancer Institute awarded a $716,521 Project Grant to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate DLL3-targeted IL18-secreting Chimeric Antigen Receptor (CAR) T cells as a novel immunotherapy for small cell lung cancer (SCLC). The research addresses a critical clinical need, as SCLC currently demonstrates exceptionally poor prognosis with median...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2027. The research project investigates Fusobacterium nucleatum's impact on breast cancer progression and explores therapeutic interventions using pox micelle technology. The primary deliverables include comprehensive characterization of the tumor...